An independent jury of experts will evaluate entries based on scientific merit, feasibility, and potential patient impact.

By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

Advances are occurring in spectroscopy, reducing the challenges of rapid signal saturation and the need for extensive sample prep.

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more accurate.

PRDX6 and GSTP1 identified as promising enzyme targets for neuroblastoma, offering an alternative to retinoic acid differentiation therapy.

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

Addressing protein aggregation, product stability, supply chains, and regulations requires multiple tools, including ...

Chrysalis partners with life science clients, from early-stage biofirms to pharmaceutical firms, CROs, and other life science ...

Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for ...

PepGen leverages a graph-based approach to improve the detection of hidden protein variants in a computationally efficient ...